ArriVent Biopharma, Inc. (AVBP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$30.95-0.26%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AVBP
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | |
|---|---|---|---|---|---|
| Operating Expenses & Income | |||||
| R&D Expenses | 144.3 | 153.4 | 79.0 | 64.9 | — |
| Operating Income | (175.9) | (177.5) | (94.3) | (74.6) | — |
| Net Income | |||||
| Net Income | (163.7) | (166.3) | (80.5) | (69.3) | — |
| Per Share | |||||
| Basic EPS | (3.44) | (4.32) | (2.56) | (32.38) | — |
| Diluted EPS | (3.44) | (4.32) | (2.56) | (32.38) | — |
| Basic Weighted Avg Shares | 47.6 | 38.5 | 31.5 | 2.1 | — |
| Diluted Weighted Avg Shares | 47.6 | 38.5 | 31.5 | 2.1 | — |
| Supplemental | |||||
| EBITDA | — | (180.6) | — | — | — |
| EBIT | (175.9) | (177.5) | (94.3) | (74.6) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.